Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class IL-4Rα antagonist. In 2024, it generated $14.179 billion in sales (23% YoY growth).

Please provide your email address to receive an email when new articles are posted on . Dupilumab and mepolizumab are the only FDA-approved biologics for adults with COPD and an eosinophilic phenotype ...

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...